CN113908176B - Composition for preventing and treating food allergy - Google Patents
Composition for preventing and treating food allergy Download PDFInfo
- Publication number
- CN113908176B CN113908176B CN202111447581.XA CN202111447581A CN113908176B CN 113908176 B CN113908176 B CN 113908176B CN 202111447581 A CN202111447581 A CN 202111447581A CN 113908176 B CN113908176 B CN 113908176B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- bifidobacterium longum
- animalis
- bifidobacterium animalis
- longum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000004262 Food Hypersensitivity Diseases 0.000 title claims abstract description 32
- 206010016946 Food allergy Diseases 0.000 title claims abstract description 32
- 235000020932 food allergy Nutrition 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 56
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 56
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 46
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 36
- 229960001340 histamine Drugs 0.000 abstract description 18
- 235000013305 food Nutrition 0.000 abstract description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 230000003266 anti-allergic effect Effects 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 230000004069 differentiation Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 108090000978 Interleukin-4 Proteins 0.000 abstract description 3
- 210000003651 basophil Anatomy 0.000 abstract description 3
- 210000001165 lymph node Anatomy 0.000 abstract description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 27
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 239000006041 probiotic Substances 0.000 description 16
- 235000018291 probiotics Nutrition 0.000 description 16
- 230000000529 probiotic effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000013566 allergen Substances 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 230000000172 allergic effect Effects 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 241000186361 Actinobacteria <class> Species 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 241001430332 Bifidobacteriaceae Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010061711 Gliadin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a composition for preventing and treating food allergy, which comprises bifidobacterium longum and bifidobacterium animalis; latin name of the Bifidobacterium longum: bifidobacterium longum, accession number: CICC 6188; latin name of the bifidobacterium animalis: bifidobacterium animalis, accession number: CICC 6165. The composition can effectively inhibit Th0 from differentiating to Th2 through synergistic effect of bifidobacterium longum and bifidobacterium animalis, obviously regulate and raise IgE and IL-4, enhance Treg differentiation and IL-10 secretion in mesenteric lymph nodes, reduce basophil histamine secretion, and reduce food anaphylaxis, thereby regulating or improving intestinal environment of human body to achieve antiallergic effect.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a composition for preventing and treating food allergy.
Background
Food allergy is a worldwide common immunological disorder, a pathological, potentially fatal allergic reaction caused by normal food. Most food allergens are highly thermostable and pH stable, have high sequence conservation, and are capable of cross-reacting to varying degrees between species.
Currently, a common approach to alleviating and controlling allergies caused by various allergens in foods is to avoid the consumption of antiallergic drugs containing the corresponding allergens and their products, their removal of the corresponding allergens for foods and clinical use in therapy. Avoiding eating food containing allergen and its products can effectively reduce the probability of allergy occurrence, but can not fundamentally avoid eating one food. The allergen-removing method of the food can obviously reduce the immune activity of the allergen, but can not fundamentally relieve or control the allergy of the food, and the food is easy to lose the structure, the sensory property and the nutritional value of the food. Clinical therapeutic drugs are mainly specific immunotherapy to induce tolerance of the organism to allergens, and when the host comes into contact with the allergens again, allergic reactions of different degrees can be induced.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems in the related art to some extent. To this end, an object of the present invention is to provide a composition for preventing and treating food allergy.
In a first aspect the present invention provides a composition for controlling food allergy comprising bifidobacterium longum and bifidobacterium animalis; latin name of the Bifidobacterium longum: bifidobacterium longum, accession number: CICC 6188; latin name of the bifidobacterium animalis: bifidobacterium animalis, accession number: CICC 6165.
According to the composition for preventing and treating allergy, disclosed by the embodiment of the invention, through the synergistic effect of bifidobacterium longum and bifidobacterium animalis, the differentiation of Th0 into Th2 can be effectively inhibited, igE and IL-4 are obviously regulated and increased, treg differentiation and IL-10 secretion in mesenteric lymph nodes are enhanced, and the secretion of basophil histamine is reduced, so that food allergy is reduced, and the intestinal environment of a human body is regulated or improved to achieve an antiallergic effect.
Optionally, the bifidobacterium longum and the bifidobacterium animalis are described as 1:1 proportion of intake of 1×10 per day 10 ～1×10 13 cfu。
In a second aspect of the invention, a medicament for the prevention and treatment of food allergy is presented, comprising bifidobacterium longum and bifidobacterium animalis; latin name of the Bifidobacterium longum: bifidobacterium longum, accession number: CICC 6188; latin name of the bifidobacterium animalis: bifidobacterium animalis, accession number: CICC 6165.
According to the allergy prevention and treatment medicine provided by the embodiment of the invention, through the synergistic effect of bifidobacterium longum and bifidobacterium animalis, the differentiation of Th0 to Th2 can be effectively inhibited, igE and IL-4 are obviously regulated and increased, treg differentiation and IL-10 secretion in mesenteric lymph nodes are enhanced, and the secretion of basophil histamine is reduced, so that food allergy is reduced, and the intestinal environment of a human body is regulated or improved, so that the allergy prevention effect is achieved.
Optionally, the medicament is one of a tablet, a granule, a powder, a capsule, a solution, a suspension and a freeze-dried preparation.
Optionally, pharmaceutically acceptable auxiliary agents are also included, including at least one of stabilizers, wetting agents, emulsifiers, binders.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
FIG. 1 is the effect of Bifidobacterium longum and Bifidobacterium animalis on specific IgE in serum of allergic patients according to example 2 of the present invention;
FIG. 2 is the effect of histamine content in serum of Bifidobacterium longum and Bifidobacterium animalis allergic patients according to example 3 of the present invention;
FIG. 3 is the effect of specific IgE in serum of Bifidobacterium longum allergic patients according to example 4 of the present invention;
FIG. 4 is the effect of histamine content in serum of Bifidobacterium longum allergic patients according to example 5 of the present invention.
Detailed Description
The technical scheme of the invention is described below through specific examples. It is to be understood that the mention of one or more method steps of the present invention does not exclude the presence of other method steps before and after the combination step or that other method steps may be interposed between these explicitly mentioned steps; it should also be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Moreover, unless otherwise indicated, the numbering of the method steps is merely a convenient tool for identifying the method steps and is not intended to limit the order of arrangement of the method steps or to limit the scope of the invention in which the invention may be practiced, as such changes or modifications in their relative relationships may be regarded as within the scope of the invention without substantial modification to the technical matter.
In order to better understand the above technical solution, exemplary embodiments of the present invention are described in more detail below. While exemplary embodiments of the invention are shown, it should be understood that the invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The test materials adopted by the invention are all common commercial products and can be purchased in the market.
The invention will now be described with reference to specific examples, which are intended to be illustrative only and not limiting in any way.
Example 1
1. Isolation of strains
(1) Sampling natural fermented yoghourt by using a sterilized sampling spoon, wherein the sampling process avoids other parts contacting the sample to prevent pollution, taking 1mL of natural fermented yoghourt under the aseptic condition, placing the natural fermented yoghourt into a triangular flask with 99mL of sterile physiological saline with the concentration of 0.85%, and oscillating for 15min to ensure that the sample is fully and uniformly mixed to prepare a suspension; serial 10-fold gradient dilution of the suspension is carried out according to a multiple dilution method, and 100 mu L of each gradient is evenly coated on 10g of MRS peptone, 5g of beef powder and K 2 HPO 4 ·7H 2 O2 g, tri-ammonium citrate 2g, CH 3 COONa·3H 2 O5 g, glucose 20g, tween 80 1mL and MgSO 4 ·7H 2 O 0.2g、MnSO 4 ·4H 2 O0.05 g and distilled water 1000mL, then placing the culture on an anaerobic tank, and carrying out anaerobic culture at 37 ℃ for overnight, wherein the MRS culture plate is visible to grow with characteristic colonies (characterized by medium size, bulges, bluish white color, wetting and regular edges, circular colonies with diameter of 1.5 mm+/-1 mm) on the next day; inoculating the selected characteristic colony on MRS plate culture medium for purification treatment by second generation streak according to the inoculation amount of 1%, and performing anaerobic activation for 1 day at 37 ℃ to obtain a culture for later use.
(2) Primer: 27F:5'AGAGTTTGATCMTGGCTCAG 3';1492R:5'GGTTACCTTGTTACGACTT 3'. Extracting the DNA of the culture by using a bacterial DNA kit, amplifying the 16SrDNA fragment by PCR to obtain an amplified product, and then sending the amplified product to a biological engineering Co., ltd for sequencing to obtain the full length of the 16 SrDNA. The 16SrDNA is subjected to Blast comparison in an Eztax database, homology comparison is carried out, the strain belongs to bifidobacterium longum (Bifidobacterium longum) and bifidobacterium animalis (Bifidobacterium animalis) respectively, and classification units are respectively as follows: bacteria; actinomycetes; actinomycetes; bifidobacteria; bifidobacteriaceae; bifidobacterium longum and bacteriocins; actinomycetes; actinomycetes; bifidobacteria; bifidobacteriaceae; bifidobacterium animalis.
Example 2
(1) 10 patients with food allergy were studied, and 10 patients were randomized into a control group (3 persons), a placebo group (3 persons) and a probiotic group (4 persons). During the test period, probiotic subjects took 1 "of the independent packages 1" each day after 1 hour of meal: 1 mixing Bifidobacterium longum and Bifidobacterium animalis (2 g, viable count 0.5X10) 13 CFU/g), placebo powder (2 g of oven-dried porous dextrin) was taken 1 hour after each meal of day for 28 consecutive days. All people had consistent food consumption before and during the trial. A blood sample of the subject was collected on day 28 of probiotic or placebo administration and subjected to high speed centrifugation to obtain serum for immune index detection.
(2) Determination of specific IgE in serum: the measurement was performed by an enzyme-linked immunosorbent assay (ELISA). Wheat gliadin was diluted to 15. Mu.g/mL with PBS and then fixed in 96-well plates overnight at 4℃and washed 3 times with 200. Mu.L of PBS and blocked with 200. Mu.L of 5% BSA at 25℃for 2h. Afterwards, the plates were washed 3 times and incubated with 100. Mu.L of serum from 10 subjects (1:30 dilution) for 1.5 hours at 37℃and non-allergic serum was used as negative control. After 3 washes, 100. Mu.L of HRP-conjugated goat anti-human IgE (1:5000) was added to each well and incubated at 37℃for 1.5 hours. Then 100. Mu.L of tetramethylbenzidine solution was added to each well and incubated at 37℃for 15 minutes. The color reaction was stopped by 50. Mu.L of 2M H2SO4 solution. The optical density of each well was measured at 450nm using a microplate reader (Molecular Devices, USA).
The results are shown in figure 1, with no significant change in IgE levels in the serum of the placebo-group food allergy population compared to the control group, and with significantly lower IgE levels in the serum of the probiotic-group food allergy population for 28 days of bifidobacterium longum and bifidobacterium animalis intervention than in the control and placebo groups. The intervention of bifidobacterium longum and bifidobacterium animalis has an adjusting effect on food allergy patients, and can adjust or improve the intestinal environment of human bodies to achieve the antiallergic effect.
Example 3
(1) 10 patients with food allergy were studied, and 10 patients were randomized into a control group (3 persons), a placebo group (3 persons) and a probiotic group (4 persons). During the test period, probiotic subjects took 1 "of the independent packages 1" each day after 1 hour of meal: 1 mixing Bifidobacterium longum and Bifidobacterium animalis (4 g, viable count 1×10) 13 CFU/g), placebo powder (4 g of oven-dried porous dextrin) was taken 1 hour after each meal of day for 28 consecutive days. All people had consistent food consumption before and during the trial. A blood sample of the subject was collected on day 28 of probiotic or placebo administration and subjected to high speed centrifugation to obtain serum for immune index detection.
(2) Determination of histamine in serum: histamine in serum was measured using a human Histamine ELISA kit (available from Thermo Fisher Scientific) according to the instructions and the absorbance OD of each well was measured at 450 nm.
The results are shown in figure 2, with no significant change in the level of histamine in the serum of the placebo-group food allergy population compared to the control group, and with the probiotic-group food allergy population with significantly lower levels of histamine in the serum of the control group and placebo group 28 days of bifidobacterium longum and bifidobacterium animalis intervention. The intervention of bifidobacterium longum and bifidobacterium animalis has an adjusting effect on food allergy patients, and can adjust or improve the intestinal environment of human bodies to achieve the antiallergic effect.
Example 4
(1) 10 patients with food allergy were studied, and 10 patients were randomly divided into a control group (3 persons), a placebo group (3 persons), a probiotic group (4 persons), a bifidobacterium longum group (4 persons) and a bifidobacterium animalis group (4 persons). During the test period, probiotic subjects took 1 "of the independent packages 1" each day after 1 hour of meal: 1 mixing Bifidobacterium longum and Bifidobacterium animalis (2 g, viable count 0.5X10) 13 CFU/g), and independently packaged Bifidobacterium longum (2 g, viable count 0.5X10) was taken 1 hour after each meal 13 CFU/g), independently packaged Bifidobacterium longum (2 g, viable count 0.5X1) was taken 1 hour after each meal of animals0 13 CFU/g), placebo powder (2 g of oven-dried porous dextrin) was taken 1 hour after each meal of day for 28 consecutive days. All people had consistent food consumption before and during the trial. A blood sample of the subject was collected on day 28 of probiotic or placebo administration and subjected to high speed centrifugation to obtain serum for immune index detection.
(2) Determination of specific IgE in serum: the measurement was performed by an enzyme-linked immunosorbent assay (ELISA). Wheat gliadin was diluted to 15. Mu.g/mL with PBS and then fixed in 96-well plates overnight at 4℃and washed 3 times with 200. Mu.L of PBS and blocked with 200. Mu.L of 5% BSA at 25℃for 2h. Afterwards, the plates were washed 3 times and incubated with 100. Mu.L of serum from 10 subjects (1:30 dilution) for 1.5 hours at 37℃and non-allergic serum was used as negative control. After 3 washes, 100. Mu.L of HRP-conjugated goat anti-human IgE (1:5000) was added to each well and incubated at 37℃for 1.5 hours. Then 100. Mu.L of tetramethylbenzidine solution was added to each well and incubated at 37℃for 15 minutes. The color reaction was stopped by 50. Mu.L of 2M H2SO4 solution. The optical density of each well was measured at 450nm using a microplate reader (Molecular Devices, USA).
The results are shown in figure 3, there was no significant change in the level of histamine in the serum of the placebo-group food allergy population compared to the control group, the level of histamine in the serum of the probiotic-group food allergy population with bifidobacterium longum and bifidobacterium animalis was significantly lower than in the control group and placebo group after 28 days of probiotic-group food allergy population with 28 days of bifidobacterium longum intervention, but the overall level was not high. The animal bifidobacteria, the bifidobacterium longum group and the probiotics group can be interfered to have a regulating effect on food allergy, and can regulate or improve the intestinal environment of a human body to achieve the antiallergic effect, but the three effects are different, and the probiotics group has obvious differences with the bifidobacterium longum group and the bifidobacterium animalis, so that the bifidobacterium longum and the bifidobacterium animalis have a synergistic effect, and the effect is better than that of the bifidobacterium longum group and the bifidobacterium animalis.
Example 5
(1) Taking 14 food allergy patients as a studySubject, 10 patients were randomized into control (3 persons), placebo (3 persons), probiotic (4 persons), bifidobacterium longum (4 persons) and bifidobacterium animalis (4 persons). During the test period, probiotic subjects took 1 "of the independent packages 1" each day after 1 hour of meal: 1 mixing Bifidobacterium longum and Bifidobacterium animalis (4 g, viable count 1×10) 13 CFU/g), and independently packaged Bifidobacterium longum (4 g, viable count 1×10) 13 CFU/g), independently packaged Bifidobacterium longum (4 g, viable count 1×10) was taken 1 hour after each meal of animals 13 CFU/g), placebo powder (4 g of oven-dried porous dextrin) was taken 1 hour after each meal of day for 28 consecutive days. All people had consistent food consumption before and during the trial. A blood sample of the subject was collected on day 28 of probiotic or placebo administration and subjected to high speed centrifugation to obtain serum for immune index detection.
(2) Determination of histamine in serum: histamine in serum was measured using a human Histamine ELISA kit (available from Thermo Fisher Scientific) according to the instructions and the absorbance OD of each well was measured at 450 nm.
The results are shown in figure 4, there was no significant change in the level of histamine in the serum of the placebo-group food allergy population compared to the control group, the level of histamine in the serum of the probiotic-group food allergy population with bifidobacterium longum and bifidobacterium animalis was significantly lower than in the control group and placebo group after 28 days of probiotic-group food allergy population with 28 days of bifidobacterium longum intervention, but the overall level was not high. The animal bifidobacteria, the bifidobacterium longum group and the probiotics group can be interfered to have a regulating effect on food allergy, and can regulate or improve the intestinal environment of a human body to achieve the antiallergic effect, but the three effects are different, and the probiotics group has obvious differences with the bifidobacterium longum group and the bifidobacterium animalis, so that the bifidobacterium longum and the bifidobacterium animalis have a synergistic effect, and the effect is better than that of the bifidobacterium longum group and the bifidobacterium animalis.
In summary, bifidobacterium longum and bifidobacterium animalis of the embodiments of the present invention are able to significantly reduce the content of histamine in the serum and the allergic response specific antibodies IgE of food allergy patients, thereby alleviating the allergic response. Thus, the bifidobacterium longum and bifidobacterium animalis are useful for alleviating food allergy.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms should not be understood as necessarily being directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Further, one skilled in the art can engage and combine the different embodiments or examples described in this specification.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (5)
1. A composition for preventing and treating food allergy, comprising bifidobacterium longum and bifidobacterium animalis; latin name of the Bifidobacterium longum: bifidobacterium longum, accession number: CICC 6188; latin name of the bifidobacterium animalis: bifidobacterium animalis, accession number: CICC 6165; the bifidobacterium longum and the bifidobacterium animalis are described as 1:1 proportion of intake of 1×10 per day 10 ～1×10 13 cfu。
2. A medicament for preventing and treating food allergy, which is characterized by comprising bifidobacterium longum and bifidobacterium animalis; latin name of the Bifidobacterium longum: bifidobacterium longum the number of the individual pieces of the plastic,preservation number: CICC 6188; latin name of the bifidobacterium animalis: bifidobacterium animalis, accession number: CICC 6165; the bifidobacterium longum and the bifidobacterium animalis are described as 1:1 proportion of intake of 1×10 per day 10 ～1×10 13 cfu。
3. The medicament of claim 2, wherein the medicament is in one of a tablet, a granule, a powder, a capsule, a solution, a suspension.
4. The medicament of claim 2, wherein the medicament is in a lyophilized formulation.
5. The medicament of claim 2, further comprising pharmaceutically acceptable adjuvants including at least one of stabilizers, wetting agents, emulsifiers, binders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111447581.XA CN113908176B (en) | 2021-11-30 | 2021-11-30 | Composition for preventing and treating food allergy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111447581.XA CN113908176B (en) | 2021-11-30 | 2021-11-30 | Composition for preventing and treating food allergy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113908176A CN113908176A (en) | 2022-01-11 |
| CN113908176B true CN113908176B (en) | 2024-02-09 |
Family
ID=79248525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111447581.XA Active CN113908176B (en) | 2021-11-30 | 2021-11-30 | Composition for preventing and treating food allergy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113908176B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| CN103820357A (en) * | 2013-12-30 | 2014-05-28 | 上海交大昂立股份有限公司 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN108770974A (en) * | 2018-06-15 | 2018-11-09 | 广东燕岭生命科技股份有限公司 | A kind of antianaphylactic probiotic gel candy and preparation method thereof |
| CN112273657A (en) * | 2019-07-22 | 2021-01-29 | 安琪酵母股份有限公司 | Probiotic composition for preventing or improving allergic diseases, preparation method and application |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE546149T1 (en) * | 2009-05-11 | 2012-03-15 | Nestec Sa | PREVENTION AND TREATMENT OF ALLERGIC DIARRHEA |
| EP3091861A1 (en) * | 2013-11-25 | 2016-11-16 | Nestec S.A. | Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations |
-
2021
- 2021-11-30 CN CN202111447581.XA patent/CN113908176B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| CN103820357A (en) * | 2013-12-30 | 2014-05-28 | 上海交大昂立股份有限公司 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN108770974A (en) * | 2018-06-15 | 2018-11-09 | 广东燕岭生命科技股份有限公司 | A kind of antianaphylactic probiotic gel candy and preparation method thereof |
| CN112273657A (en) * | 2019-07-22 | 2021-01-29 | 安琪酵母股份有限公司 | Probiotic composition for preventing or improving allergic diseases, preparation method and application |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113908176A (en) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oak et al. | The effects of probiotics in lactose intolerance: A systematic review | |
| RU2603285C2 (en) | Bifidobacterium bifidum strains for application in gastrointestinal diseases | |
| CN106834187B (en) | Bifidobacterium bifidum and application thereof | |
| RU2539514C2 (en) | Nutritional composition containing strains bifidobacterium longum and relieving symptoms of food allergy, especially in infants and children | |
| Agarwal et al. | Feasibility studies to control acute diarrhoea in children by feeding fermented milk preparations Actimel and Indian Dahi | |
| JP5117171B2 (en) | Antiallergic lactic acid bacteria | |
| KR101487210B1 (en) | Anti-allergic composition | |
| CN101328468A (en) | Antiallergic lactic acid bacteria | |
| US20010051152A1 (en) | Somnogenic activity | |
| Lei et al. | Screening of probiotic Lactobacilli with potential anti-allergic activity based on hyaluronidase inhibition and degranulation of RBL-2H3 cells in vitro | |
| JP2008502606A (en) | Lactic acid bacteria and their use in the prevention of diarrhea | |
| CN103550258B (en) | The purposes of lactobacillus strain immunity moderation reaction | |
| Piano et al. | Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form | |
| Marcinkowska et al. | A review of probiotic supplementation and feasibility of topical application for the treatment of pediatric atopic dermatitis | |
| CN112375722B (en) | Lactobacillus casei LC-12 for improving allergy, and product and application thereof | |
| CN111254087B (en) | Lactobacillus helveticus with high adhesion performance and function of enhancing immunity and application thereof | |
| CN113908176B (en) | Composition for preventing and treating food allergy | |
| CN111743158A (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
| CN110892914A (en) | New application of lactobacillus paracasei K56 in improvement of asthma and related allergic symptoms | |
| CN102028224B (en) | Antiallergic lactobacillus | |
| CN114672445A (en) | Lactobacillus rhamnosus strain LRa90, application thereof in preparation of product for treating allergy and/or inhibiting pathogenic bacteria, and product | |
| AU2019257482B2 (en) | Composition for promoting glucolipid metabolism, and preparation and application thereof | |
| US20110052553A1 (en) | Strain of lactobacillus plantarum lp28 and its use in treating hypersensitivity reactions | |
| CN114317326B (en) | Lactobacillus sake for relieving anaphylactic reaction and preparation method thereof | |
| TWI386163B (en) | Anti-allergy lactic acid bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |